Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 21:15:1447450.
doi: 10.3389/fphar.2024.1447450. eCollection 2024.

A review of the fernane-type triterpenoids as anti-fungal drugs

Chun-Yue Liu  1   2 , Lu Zhang  1 , Si-Xuan Liu  1 , Yong-Fu Lu  1 , Chang Li  1 , Yue-Hu Pei  1
Affiliations
Review

A review of the fernane-type triterpenoids as anti-fungal drugs

Chun-Yue Liu et al. Front Pharmacol. .

Abstract

Human fungal pathogens could cause a broad plethora of infections in both the immunocompetent and immunocompromised host. Fungal infections have become important causes of morbidity and mortality in recent years, the current arsenal of anti-fungal therapies was restricted. Ibrexafungerp was a novel, highly bioavailable glucan synthase inhibitor formulated for both intravenous and oral administration being developed by Scynexis; it was also the first novel anti-fungal drug class approved in more than 20 years. Ibrexafungerp was one semi-synthetic derivative of enfumafungin, a natural product isolated from fungi. This review reported the discovery of enfumafungin and ibrexafungerp, their anti-fungal mechanism, summed up 63 fernane-type triterpenoids from natural products, including 49 from plants, 9 from fungi and 5 from lichen. In addition, the review summarized the progress of enzymes responsible for the biosynthesis of type II fernane triterpenoid (enfumafungin skeleton) and type I fernane triterpenoid (polytolypin skeleton). The good example kept our confidence up for searching for new leading compounds and discovering drugs from fungi.

Keywords: anti-fungal; enfumafungin; fernane type; ibrexafungerp; triterpenoid.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The synthetic procedure from enfumafungin to ibrexafungerp.
FIGURE 2
FIGURE 2
Key milestones in the development of oral ibrexafungerp from enfumafungin.
FIGURE 3
FIGURE 3
Fernane type tri-terpenoids (1–11) from natural products.
FIGURE 4
FIGURE 4
Fernane type tri-terpenoids (12–29) from natural products.
FIGURE 5
FIGURE 5
Fernane type tri-terpenoids (30–49) from natural products.
FIGURE 6
FIGURE 6
Fernane type tri-terpenoids (50–63) from natural products.
FIGURE 7
FIGURE 7
Biosynthesis gene cluster of enfumafungin.
FIGURE 8
FIGURE 8
Biosynthesis pathway of polytolypin.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abdel- Razek A. S., Hamed A., Frese M., Sewald N., Shaaban M. (2018). Penicisteroid C: new polyoxygenated steroid produced by co-culturing of Streptomyces piomogenuswith Aspergillus Niger. Steroids 138, 21–25. 10.1016/j.steroids.2018.06.005 - DOI - PubMed
    1. Aly A. H., Debbab A., Proksch P. (2011). Fifty years of drug discovery from fungi. Fungal Divers. 50, 3–19. 10.1007/s13225-011-0116-y - DOI
    1. Anderson M. R., Klink K., Cohrssen A. (2004). Evaluation of vaginal complaints. JAMA 291 (11), 1368–1379. 10.1001/jama.291.11.1368 - DOI - PubMed
    1. Angulo D. A., Alexander B., Rautemaa-Richardson R., Alastruey-Izquierdo A., Hoenigl M., Ibrahim A. S., et al. (2022). Ibrexafungerp, a novel triterpenoid antifungal in development for the treatment of mold infections. J. Fungi 8 (11), 1121. 10.3390/jof8111121 - DOI - PMC - PubMed
    1. Apgar J. M., Wilkening R. R., Parker D. L. J., Meng D., Wildonger K. J., Sperbeck D., et al. (2021). Ibrexafungerp: an orally active β-1,3-glucan synthesis inhibitor. BIOORG Med. Chem. Lett. 32, 127661. 10.1016/j.bmcl.2020.127661 - DOI - PubMed

LinkOut - more resources